FCA
CBIO

FinTrust Capital Advisors’s Crescent Biopharma CBIO Stock Holding History

FinTrust Capital Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed – – 1248
2022
Q1 		$0 Hold
2
– – ﹤0.01% 1249
2021
Q4 		$0 Buy
+2
New +$363 ﹤0.01% 1215

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

FinTrust Capital Advisors's CBIO Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of Crescent Biopharma (CBIO) in Q2 2022, closing a stake of 2 shares.

FinTrust Capital Advisors first reported a position in CBIO in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2022.

  • FinTrust Capital Advisors reported no remaining Crescent Biopharma position as of Q2 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 2 Crescent Biopharma shares in Q2 2022.
  • FinTrust Capital Advisors first reported a position in Crescent Biopharma in Q4 2021 and held it in 2 quarters.
  • FinTrust Capital Advisors's Crescent Biopharma position peaked at $0 in Q1 2022.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.